/PRNewswire/ Rejuvenate Biomed NV ("Rejuvenate"), a biomedical company developing novel combination drugs for age-related diseases, today provides an update.
Rejuvenate Biomed raises a EUR 15.7 million Series B to accelerate clinical development of its sarcopenia treatment for healthy aging Heusden-Zolder, Belgium, Schlieren, Zürich, Switzerland, and Luxembourg, Grand Duchy of Luxembourg, 12 October 2021 – Rejuvenate Biomed NV (‘Rejuvenate&rsqu.
Search jobs 02-Mar-2021 Rejuvenate Biomed Secures EUR 3.2 Million Series A Round to Advance Development of Healthy Aging Products
Rejuvenate Biomed Secures EUR 3.2 Million Series A Round to Advance Development of Healthy Aging Products
Heusden-Zolder, Belgium, 2 March 2021 – Rejuvenate Biomed NV (“Rejuvenate”), a biomedical company developing prescription drugs for age-related diseases, announces it has completed a EUR 3.2 million Series A round. The funding is being used to advance the development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-induced and age-related muscle failure).
The financing included lead investor Vesalius Biocapital III and private non-disclosed investors, as well as existing investors. Additionally, Rejuvenate gratefully acknowledges the ongoing support of Flanders Innovation and Entrepreneurship (VLAIO) in non-dilutive funding. Concurrent with the closing, the co